Osteonecrosis Due to Drugs, Jaw
8
2
2
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
12.5%
1 terminated out of 8 trials
80.0%
-6.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (8)
Medical and Surgical Treatment of MRONJ (Medication-related Osteonecrosis of the Jaw Bones)
Predictive Score for Maxillary Osteonecrosis After Invasive Oral Surgery
Human Amniotic Membrane (hAM) for Stage II Maxillomandibular Osteonecrosis Management
Medication Related Osteonecrosis of the Jaws (MRONJ) in a Cohort of Patients Treated by Antiresorptive Drugs
Photobiomodulation in Oral Lesions Resulting From Anti-neoplastic Prevention
Antiresorptive Drug Continuation Compared With Drug Holiday in Cancer Patients Needing Tooth Extraction
Plasma Rich in Growth Factors for Treatment of Medication Related Osteonecrosis of the Jaw
Use of Topical Phenytoin in Bisphosphonate-related Osteonecrosis of the Mandible